07, 2019 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading in Organogenesis Holdings Inc. (Nasdaq: ORGO) is

Köp aktien Organogenesis Holdings Inc. - Class A (ORGO). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid.

_ Organogenesis Holdings Inc. on Tuesday reported fourth-quarter net income of $18.5 million, after reporting a loss in the same period a year earlier. 2021-02-10 · Organogenesis Holdings Inc. (NASDAQ:ORGO) has a beta value of 1.32 and has seen 1,130,786 shares traded in the last trading session. The company, currently valued at $1.84 Billion, closed the last trade at $14.41 per share which meant it gained $0.68 on the day or 4.95% during that session. 2 dagar sedan · Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports 2021-04-15 · Organogenesis Holdings Inc. found using ticker (ORGO) now have 4 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 10 and 8 and has a mean target at 9.25. Organogenesis Holdings Inc (US:ORGO) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.

Organogenesis holdings

Organogenesis Holdings hasn't issued any earnings guidance for the time being. The upcoming fiscal year's revenue expected to be between $390,000,000 and $405,000,000. How To Listen To The Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. Description: Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. Get the latest Organogenesis Holdings Inc (ORGO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

2021-01-13 · Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics

The stock has moved higher by 33.8% in the past month, while it is also above its 20 day SMA Organogenesis Holdings Inc. operates as a holding company. The Company, through its subsidiaries, focuses on development, manufacturing, and commercializing drugs and medicines for wound care, 2021-04-22 · Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2021 Financial Results on May 10, 2021 CANTON, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr 1 week ago - GlobeNewsWire Organogenesis Holdings Inc. - Class A: ISIN-Sektor-Bransch-Kortnamn: ORGO: Introduktionsdatum-Belåningsgrad-Säkerhetskrav: 200 % Organogenesis Holdings Inc. (NASDAQ:ORGO) has been given an average recommendation of "Buy" by the six analysts that are covering the stock, Marketbeat Ratings reports.

07, 2019 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading in Organogenesis Holdings Inc. (Nasdaq: ORGO) is

US0079241032 AEG. AERCAP HOLDINGS N.V. O. NL0000687663 AER. AERIE PHARMACEUTICALS. Advocate Hospital System · Bactiguard AB · Christie Medical Holdings, Inc. Neurology Group of Bergen County, P.A. · Organogenesis · Pharmena North Mölnlycke Holding Ab Guide 2021.

Organogenesis was founded in 1985 as a spin-off of technology developed at the Massachusetts Institute of Technology (MIT). Our long and successful history of empowering healing began with the introduction of Apligraf ®, the first and still the only living cell-based product that is FDA approved to treat both diabetic foot ulcers and venous leg ulcers. Organogenesis Holdings Inc. (NASDAQ:ORGO) has been given an average recommendation of "Buy" by the six analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the Organogenesis Holdings Inc.’s market cap currently stands at around $2.97 Billion, with investors looking forward to this quarter’s earnings report slated for May 10, 2021.
Soka pengar till korkort

The following materials from the Annual Report of Organogenesis Holdings Inc. on Form 10-K for the year ended December 31, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2019 and December 31, 2018 of Organogenesis Holdings Inc., (ii) Consolidated Statements of Operations for the years ended December 31, 2019, 2018, and 2017 Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2020 Earnings Conference Call March 16, 2021 5:00 PM ET Company Participants. Gary Gillheeney - President and CEO. Dave Francisco - CFO. Conference CANTON, Mass.

Data Provided by Refinitiv.
Bytt adresse posten

Organogenesis Holdings Inc. - Class A: ISIN-Sektor-Bransch-Kortnamn: ORGO: Introduktionsdatum-Belåningsgrad-Säkerhetskrav: 200 %

Data Provided by Refinitiv.